This lawsuit follows receipt of a Notice of Paragraph IV Certification stating that Amneal submitted an Abbreviated New Drug Application ... version of Xifaxan (rifaximin) 550 mg tablets.
and its subsidiary Salix Pharmaceuticals announced a legal victory in the ongoing patent litigation concerning their drug XIFAXAN (rifaximin) 550 mg. The U.S. Court of Appeals for the Federal ...
and its subsidiary Salix Pharmaceuticals announced a legal victory in the ongoing patent litigation concerning their drug XIFAXAN (rifaximin) 550 mg. The U.S. Court of Appeals for the Federal ...
LAVAL, QC - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its subsidiary Salix Pharmaceuticals announced a legal victory in the ongoing patent litigation concerning their drug XIFAXAN ...
to the FDA seeking approval to market a generic version of Salix’s lead drug Xifaxan (rifaximin) 550 mg tablets. Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic ...
to the FDA seeking approval to market a generic version of Salix’s lead drug Xifaxan (rifaximin) 550 mg tablets. Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic ...
to the FDA seeking approval to market a generic version of Salix’s lead drug Xifaxan (rifaximin) 550 mg tablets. Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic ...
seeking approval to market a generic version of Xifaxan (rifaximin) 550 mg tablets. Amneal asserts that certain patents listed in the FDA’s Orange Book for Xifaxan are unenforceable, invalid, and/or ...
seeking approval to market a generic version of Xifaxan (rifaximin) 550 mg tablets. Amneal asserts that certain patents listed in the FDA’s Orange Book for Xifaxan are unenforceable, invalid, and/or ...
seeking approval to market a generic version of Xifaxan (rifaximin) 550 mg tablets. The report reveals that Amneal asserts that certain patents listed in the FDA’s Orange Book for Xifaxan are ...
to the FDA seeking approval to market a generic version of Salix’s lead drug Xifaxan (rifaximin) 550 mg tablets. Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback